Article citationsMore>>

H. A. Abdulnour, C. E. Araya and V. R. Dharnidharka, “Comparison of Generic Tacrolimus and Prograf Drug Levels in a Pediatric Kidney Transplant Program: Brief Communication,” Pediatric Transplantation, Vol. 14, No. 8, 2010, pp. 1007-1011. doi:10.1111/j.1399-3046.2010.01393.x

has been cited by the following article:

• TITLE: Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus Compared to Prograf

  AUTHORS: Vinayak Dhungel, Monica M. Colvin-Adams, Peter M. Eckman

  KEYWORDS: Generic Tacrolimus; Heart Transplant

  JOURNAL NAME: Open Journal of Organ Transplant Surgery, Vol.3 No.2, May 15, 2013

  ABSTRACT: Calcineurin inhibitors are the cornerstone of solid organ transplant immunosuppression. Tacrolimus has only recently become available in a non-branded formulation, and there is little data on the efficacy and safety of generic tacrolimus, particularly following heart transplant. We performed a retrospective analysis of 21 consecutive patients who were treated with generic tacrolimus following heart transplant and compared rate of biopsy-proven acute cellular rejection to historical controls who were treated with Prograf. No significant difference in biopsy-proven acute cellular rejection was noted between the groups and rates of opportunistic infection and death were comparable. Although limited by the single-center, retrospective design, this preliminary data may be useful to clinicians facing the option of initiating generic tacrolimus following heart transplant.